Christine Mannhalter

List of Publications by Year in Descending Order

311 papers	10,026 citations	54 h-index	81 g-index
318 ext. papers	10,858 ext. citations	5.2 avg, IF	5.35 L-index

#	Paper	IF	Citations
311	Ex Vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small Interfering RNA. *Thrombosis and Haemostasis*, **2020**, 120, 1483	7	
310	Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1214-1222	5.9	
309	Genetics of Vascular Diseases. *Learning Materials in Biosciences*, **2019**, 245-269	0.3	
308	High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB). *Haemophilia*, **2018**, 24, 405-413	3.3	29
307	Impact of Escherichia coli K12 and O18:K1 on human platelets: Differential effects on platelet activation, RNAs and proteins. *Scientific Reports*, **2018**, 8, 16145	4.9	3
306	Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. *Annals of Surgery*, **2018**, 268, 894-902	7.8	43
305	Phenotyping and Target Expression Profiling of CD34/CD38 and CD34/CD38 Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. *Neoplasia*, **2018**, 20, 632-642	6.4	18
304	Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. *Annals of Hematology*, **2017**, 96, 489-495	3	14
303	Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications. *Annals of Hematology*, **2017**, 96, 1023-1031	3	17
302	Homozygous antithrombin deficiency type II causing neonatal thrombosis. *Thrombosis Research*, **2017**, 158, 134-137	8.2	5
301	Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden. *Surgical Oncology*, **2017**, 26, 395-401	2.5	18
300	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. *Cancer Cell*, **2017**, 32, 238-252.e9	24.3	150
299	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. *Oncotarget*, **2017**, 8, 23061-23072	3.3	10
298	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. *Clinical Cancer Research*, **2016**, 22, 2051-61	12.9	38
297	Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. *Leukemia*, **2016**, 30, 1861-8	10.7	44
296	FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. *Blood*, **2016**, 128, 293-6	2.2	22
295	Platelet-borne complement proteins and their role in platelet-bacteria interactions. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 2241-2252	15.4	20

294	Increased expression of transient receptor potential canonical 6 (TRPC6) in differentiating human megakaryocytes. *Cell Biology International*, **2016**, 40, 223-31	4.5	11
293	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. *Annals of Hematology*, **2015**, 94, 223-31	3	13
292	Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS). *Journal of Thrombosis and Haemostasis*, **2015**, 13, 17-22	15.4	41
291	Impact of variables of the P-selectin - P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. *Thrombosis and Haemostasis*, **2015**, 113, 806-12	7	30
290	The impact of uric acid on long-term mortality in patients with asymptomatic carotid atherosclerotic disease. *Journal of Stroke and Cerebrovascular Diseases*, **2015**, 24, 354-61	2.8	4
289	Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. *Haemophilia*, **2015**, 21, 343-50	3.3	39
288	Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. *Oncotarget*, **2015**, 6, 3071-84	3.3	34
287	Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. *Journal of the American College of Cardiology*, **2014**, 63, 630-635	15.1	153
286	Mean platelet volume predicts outcome in patients with asymptomatic carotid artery disease. *European Journal of Clinical Investigation*, **2014**, 44, 22-8	4.6	20
285	The association of the Thr715Pro P-selectin genotype with levels of P-selectin in platelet concentrates. *Vox Sanguinis*, **2014**, 107, 368-74	3.1	4
284	Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study. *British Journal of Haematology*, **2014**, 167, 547-53	4.5	3
283	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. *Leukemia Research Reports*, **2014**, 3, 8-13	0.6	10
282	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. *Blood*, **2014**, 123, 3951-62	2.2	140
281	Biomarkers for arterial and venous thrombotic disorders. *Hamostaseologie*, **2014**, 34, 115-20, 122-6, 128-30, passim	1.9	7
280	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. *Neuro-Oncology*, **2014**, 16, 1645-51	1	45
279	No impact of endogenous prothrombotic conditions on the risk of central venous line-related thrombotic events in children: results of the KIDCAT study (KIDs with Catheter Associated Thrombosis). *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1610-5	15.4	20
278	The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. *Allergy: European Journal of Allergy and Clinical Immunology*, **2014**, 69, 810-3	9.3	64
277	Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention. *Thrombosis and Haemostasis*, **2014**, 111, 1060-6	7	3

276	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. *Blood*, **2014**, 124, 817-817	2.2	5
275	Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. *American Journal of Blood Research*, **2014**, 4, 93-100	1.6	8
274	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. *Blood*, **2014**, 124, 4526-4526	2.2	
273	CYP2C9 genotype and association with bone mineral density: a pilot study. *Gene*, **2013**, 526, 295-8	3.8	2
272	Prognostic value of neutrophils in patients with asymptomatic carotid artery disease. *Atherosclerosis*, **2013**, 231, 274-80	3.1	20
271	UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians. *Cancer Epidemiology*, **2013**, 37, 625-8	2.8	10
270	Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. *International Journal of Cardiology*, **2013**, 166, 126-31	3.2	22
269	Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. *Allergy: European Journal of Allergy and Clinical Immunology*, **2013**, 68, 713-23	9.3	8
268	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. *Blood*, **2013**, 121, 1175-83	2.2	32
267	The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. *Thrombosis and Haemostasis*, **2013**, 109, 79-84	7	12
266	Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants. *Blood*, **2013**, 122, 1654-1654	2.2	1
265	The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph+ CML. *Blood*, **2013**, 122, 3979-3979	2.2	1
264	Gene Polymorphisms and Signaling Defects **2013**, 53-102		
263	KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease. *Blood*, **2013**, 122, 4052-4052	2.2	
262	Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML. *Blood*, **2013**, 122, 3988-3988	2.2	
261	Defective diacylglycerol-induced Ca2+ entry but normal agonist-induced activation responses in TRPC6-deficient mouse platelets. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 419-29	15.4	41
260	Monitoring neutrophils and platelets during casein-induced anaphylaxis in an experimental BALB/c mouse model. *Clinical and Experimental Allergy*, **2012**, 42, 1119-28	4.1	11
259	Polymorphism of the complement 5 gene and cardiovascular outcome in patients with atherosclerosis. *European Journal of Clinical Investigation*, **2012**, 42, 921-6	4.6	19

258	Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. *Thrombosis Research*, **2012**, 129, 616-22	8.2	19
257	High levels of platelet-monocyte aggregates after valve replacement for aortic stenosis: relation to soluble P-selectin and P-selectin glycoprotein ligand-1 genes. *Thrombosis Research*, **2012**, 129, 453-8	8.2	9
256	Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. *European Journal of Cancer*, **2012**, 48, 233-6	7.5	18
255	The Thr715Pro variant impairs terminal glycosylation of P-selectin. *Thrombosis and Haemostasis*, **2012**, 108, 963-72	7	8
254	Identification of an ancient haemophilia A splice site mutation. *Thrombosis Research*, **2012**, 130, 445-50	8.2	5
253	Age-specific PCA3 score reference values for diagnosis of prostate cancer. *World Journal of Urology* , **2012**, 30, 405-10	4	11
252	Inhibitor development in two patients with mild haemophilia A - spontaneous disappearance and no recurrence of the inhibitor after re-challenge. *Wiener Klinische Wochenschrift*, **2012**, 124, 198-201	2.3	
251	Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. *European Heart Journal*, **2012**, 33, 2282-9	9.5	44
250	Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. *FASEB Journal*, **2012**, 26, 894-906	0.9	39
249	Butyrylcholinesterase activity predicts long-term survival in patients with coronary artery disease. *Clinical Chemistry*, **2012**, 58, 1055-8	5.5	21
248	Polymorphisms and noncardioembolic stroke in three case-control studies. *Cerebrovascular Diseases*, **2012**, 33, 80-5	3.2	1
247	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. *Haematologica*, **2012**, 97, 1431-8	6.6	86
246	EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. *Anticancer Research*, **2012**, 32, 4883-9	2.3	13
245	A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.. *Blood*, **2012**, 120, 2685-2685	2.2	
244	The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. *Atherosclerosis*, **2011**, 217, 135-8	3.1	5
243	The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤40 years of age). *Thrombosis and Haemostasis*, **2011**, 105, 529-34	7	28
242	The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. *Thrombosis and Haemostasis*, **2011**, 106, 908-13	7	25
241	Polymorphism of the palladin gene and cardiovascular outcome in patients with atherosclerosis. *European Journal of Clinical Investigation*, **2011**, 41, 365-71	4.6	1

240	Are inherited thrombotic risk factors associated with fibrostenosis in Crohn's disease?. *Inflammatory Bowel Diseases*, **2011**, 17, 2505-11	4.5	2
239	Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. *Thrombosis and Haemostasis*, **2011**, 106, 1020-33	7	86
238	Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. *Journal of Clinical Oncology*, **2011**, 29, 1445-51	2.2	148
237	The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. *European Journal of Echocardiography*, **2011**, 12, 744-9		22
236	Evaluation of the PC-1 K121Q and G2906C variants as independent risk factors for ischaemic stroke. *Hamostaseologie*, **2011**, 31, 196-200	1.9	1
235	Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women. *Haemophilia*, **2010**, 16, 111-7	3.3	29
234	Fixation of brain tumor biopsy specimens with RCL2 results in well-preserved histomorphology, immunohistochemistry and nucleic acids. *Brain Pathology*, **2010**, 20, 1010-20	6	18
233	Spectrum of causative mutations in patients with haemophilia A in Austria. *Thrombosis and Haemostasis*, **2010**, 104, 78-85	7	13
232	Pharmacogenetics guided anticoagulation. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48 Suppl 1, S119-27	5.9	
231	Maternal interleukin-6 (-174) C/C polymorphism is associated with chorioamnionitis and cystic periventricular leucomalacia of the preterm infant. *Journal of Perinatology*, **2010**, 30, 712-6	3.1	8
230	High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. *Molecular Oncology*, **2010**, 4, 335-46	7.9	42
229	Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study. *Translational Research*, **2010**, 156, 37-44	11	11
228	Combined effects of genetic polymorphisms of P-selectin and P-selectin glycoprotein ligand-1 on the binding of platelets to monocytes. *Thrombosis Research*, **2010**, 125, 475-7	8.2	5
227	Proliferation Kinetics of Subclones Carrying Point Mutations In the BCR-ABL TKD During TKI Treatment In CML Patients: Quantitative Monitoring by LD-PCR. *Blood*, **2010**, 116, 2269-2269	2.2	
226	Polymorphisms in inflammatory genes and the risk of ischemic stroke and transient ischemic attack: results of a multilocus genotyping assay. *Clinical Chemistry*, **2009**, 55, 134-8	5.5	23
225	Interleukin-6 G(--174)C polymorphism is associated with mental retardation in cystic periventricular leucomalacia in preterm infants. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, **2009**, 94, F304-6	4.7	13
224	Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: vienna stroke registry. *Cerebrovascular Diseases*, **2009**, 28, 499-504	3.2	25
223	DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. *Genes Chromosomes and Cancer*, **2009**, 48, 760-7	5	22

222	The inflammatory response is influenced by FXIII VAL 34 LEU polymorphism in a human LPS model. *Wiener Klinische Wochenschrift*, **2009**, 121, 515-9	2.3	5
221	Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. *European Journal of Clinical Investigation*, **2009**, 39, 497-506	4.6	26
220	P-selectin mRNA is maintained in platelet concentrates stored at 4 degrees C. *Transfusion*, **2009**, 49, 921-29	2.9	11
219	Association of periprocedural neurological deficit in carotid stenting with increased anticardiolipin antibodies. *Thrombosis Research*, **2009**, 123, 827-31	8.2	3
218	A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. *Stroke*, **2009**, 40, 683-95	6.7	102
217	Molecular Remission after Induction Chemo- Immunotherapy and Rituximab Maintenance in Previously Untreated Follicular Lymphoma.. *Blood*, **2009**, 114, 2724-2724	2.2	
216	Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 291-296	15.4	48
215	Coagulation factor XII activity, activated factor XII, distribution of factor XII C46T gene polymorphism and coronary risk: reply to a rebuttal. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1055-1056	15.4	1
214	Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. *Leukemia and Lymphoma*, **2008**, 49, 237-46	1.9	7
213	Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. *Annals of Oncology*, **2008**, 19, 1025-6	10.3	35
212	Certification of reference materials for detection of the human prothrombin gene G20210A sequence variant. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 463-9	5.9	4
211	Genetic variations and their influence on risk and treatment of venous thrombosis. *Pharmacogenomics*, **2008**, 9, 423-37	2.6	4
210	Autoimmune lymphoproliferative syndrome (ALPS) caused by Fas (CD95) mutation mimicking sarcoidosis. *American Journal of Surgical Pathology*, **2008**, 32, 329-34	6.7	6
209	P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. *Thrombosis and Haemostasis*, **2008**, 99, 899-904	7	27
208	Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 291-6	15.4	24
207	The Thr715Pro polymorphism of the P-selectin gene is not associated with ischemic stroke risk. *Stroke*, **2007**, 38, 395-7	6.7	13
206	High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. *Clinical Chemistry*, **2007**, 53, 1235-43	5.5	90
205	Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 497-502	15.4	50

204	Evidence of a U-shaped association between factor XII activity and overall survival. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1143-8	15.4	86
203	4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 2049-54	15.4	55
202	Polymorphisms in the coagulation factor VII gene and risk of primary intracerebral hemorrhage. *European Journal of Neurology*, **2007**, 14, 1098-101	6	8
201	Platelet glycoprotein Ibalpha polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease. *Annals of Hematology*, **2007**, 86, 719-25	3	2
200	Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia. *Human Genetics*, **2007**, 122, 183-90	6.3	24
199	Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. *Experimental and Clinical Endocrinology and Diabetes*, **2007**, 115, 38-41	2.3	34
198	Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). *Annals of Oncology*, **2007**, 18, 1834-41	10.3	8
197	Candidate genetic risk factors of stroke: results of a multilocus genotyping assay. *Clinical Chemistry*, **2007**, 53, 600-5	5.5	24
196	Risk of recurrence after a first venous thromboembolic event in young women. *Haematologica*, **2007**, 92, 1201-7	6.6	31
195	The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. *Thrombosis and Haemostasis*, **2007**, 98, 777-782	7	19
194	The fibrinogen -148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo. *Thrombosis Research*, **2007**, 120, 727-31	8.2	11
193	GAB2 is a novel target of 11q amplification in AML/MDS. *Genes Chromosomes and Cancer*, **2006**, 45, 798-807	3.7	39
192	A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. *International Journal of Cancer*, **2006**, 119, 1312-5	7.5	49
191	The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. *Clinical Chemistry*, **2006**, 52, 1952-7	5.5	29
190	Anti-cardiolipin antibodies and overall survival in a large cohort: preliminary report. *Clinical Chemistry*, **2006**, 52, 1040-4	5.5	13
189	Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 918-23	5.9	51
188	Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. *Clinical Chemistry*, **2006**, 52, 511-4	5.5	30
187	Factor VII gene haplotypes and risk of ischemic stroke. *Clinical Chemistry*, **2006**, 52, 1190-2	5.5	15

186	C-reactive protein 3NJTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. *Atherosclerosis*, **2006**, 188, 406-11	3.1	14
185	Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low-molecular-weight heparin (LMWH) during pregnancy. *Thrombosis and Haemostasis*, **2006**, 96, 285-9	7	9
184	Interleukin-6 and interleukin-6 promoter polymorphism (f174) G>C in patients with spontaneous venous thromboembolism. *Thrombosis and Haemostasis*, **2006**, 95, 802-806	7	28
183	Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. *Pediatric Infectious Disease Journal*, **2006**, 25, 80-1	3.4	71
182	Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. *American Journal of Surgical Pathology*, **2006**, 30, 529-36	6.7	70
181	The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. *Journal of Investigative Dermatology*, **2006**, 126, 2242-6	4.3	22
180	Laboratory methods in the haemostatic laboratory. *Thrombosis and Haemostasis*, **2006**, 96, 545-546	7	2
179	Predictive Value of Clonal Peripheral Blood TCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.. *Blood*, **2006**, 108, 2060-2060	2.2	
178	Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. *Stroke*, **2005**, 36, 1394-9	6.7	77
177	Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. *Stroke*, **2005**, 36, 1405-9	6.7	80
176	Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. *Neurology*, **2005**, 65, 1304-5	6.5	89
175	Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. *Clinical Pharmacology and Therapeutics*, **2005**, 78, 182-90	6.1	55
174	Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 949-54	15.4	170
173	Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. *European Journal of Clinical Investigation*, **2005**, 35, 731-7	4.6	42
172	High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. *Leukemia*, **2005**, 19, 1216-23	10.7	118
171	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. *European Journal of Haematology*, **2005**, 75, 73-7	3.8	3
170	Spectrum of germ-line MLH1 and MSH2 mutations in Austrian patients with hereditary nonpolyposis colorectal cancer. *Wiener Klinische Wochenschrift*, **2005**, 117, 269-77	2.3	10
169	PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. *Wiener Klinische Wochenschrift*, **2005**, 117, 707-10	2.3	7

168	4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. *European Journal of Pediatrics*, **2005**, 164, 486-90	4.1	52
167	Interleukin-1 gene cluster variants and abdominal aortic aneurysms. *Thrombosis and Haemostasis*, **2005**, 94, 646-650	7	11
166	Fractalkine receptor polymorphisms V249I and T280M as genetic risk factors for restenosis. *Thrombosis and Haemostasis*, **2005**, 94, 1251-1256	7	16
165	Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. *Thrombosis and Haemostasis*, **2005**, 93, 949-54	7	37
164	The Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms influence the late inflammatory response in human endotoxemia. *Clinical Chemistry*, **2005**, 51, 2178-80	5.5	17
163	Influence of cytochrome P450 2C9*2 and 2C9*3 variants on the risk of ischemic stroke: a cross-sectional case-control study. *Clinical Chemistry*, **2005**, 51, 1716-8	5.5	9
162	Impact of alphaENaC polymorphisms on the risk of ischemic cerebrovascular events: a multicenter case-control study. *Clinical Chemistry*, **2005**, 51, 952-6	5.5	14
161	Clinical restenosis after coronary stent implantation is associated with the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. *Clinical Chemistry*, **2005**, 51, 1661-5	5.5	25
160	Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. *Clinical Chemistry and Laboratory Medicine*, **2005**, 43, 192-4	5.9	9
159	Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation. *Clinical Chemistry and Laboratory Medicine*, **2005**, 43, 862-8	5.9	3
158	A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. *Thrombosis and Haemostasis*, **2004**, 91, 155-61	7	67
157	Interleukin-6 promoter genotype and restenosis after femoropopliteal balloon angioplasty: initial observations. *Radiology*, **2004**, 231, 839-44	20.5	19
156	Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. *Leukemia and Lymphoma*, **2004**, 45, 1453-8	1.9	6
155	Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. *Neurology*, **2004**, 63, 1087-9	6.5	173
154	CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. *Clinical Chemistry*, **2004**, 50, 2395-8	5.5	30
153	Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. *Stroke*, **2004**, 35, 1688-91	6.7	220
152	The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. *Clinical Chemistry*, **2004**, 50, 195-200	5.5	47
151	Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 430-6	15.4	23

150	The biological and clinical significance of MLL abnormalities in haematological malignancies. *European Journal of Clinical Investigation*, **2004**, 34 Suppl 2, 12-24	4.6	26
149	Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. *Leukemia*, **2004**, 18, 146-55	10.7	41
148	High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. *Leukemia*, **2004**, 18, 756-62	10.7	69
147	Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). *Leukemia*, **2004**, 18, 1102-7	10.7	33
146	Thrombophilic polymorphisms--factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations--and preterm birth. *Wiener Klinische Wochenschrift*, **2004**, 116, 622-6	2.3	21
145	T- and B-cell clonality and frequency of human herpes viruses-6, -8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma. *Hematological Oncology*, **2004**, 22, 169-77	1.3	28
144	Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. *Journal of the American College of Cardiology*, **2004**, 43, 950-7	15.1	76
143	Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study. *Leukemia and Lymphoma*, **2004**, 45, 971-7	1.9	4
142	The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events: the influence of other vascular risk factors. *Thrombosis Research*, **2004**, 113, 217-23	8.2	34
141	Donor heme oxygenase-1 genotype is associated with renal allograft function. *Transplantation*, **2004**, 77, 538-42	1.8	58
140	Vienna Stroke Registry. Impact of the platelet glycoprotein Ib alpha Kozak polymorphism on the risk of ischemic cerebrovascular events: a case-control study. *Blood Coagulation and Fibrinolysis*, **2004**, 15, 469-73	1	16
139	Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?. *Clinical Chemistry*, **2003**, 49, 1201-4	5.5	24
138	Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. *Transplantation*, **2003**, 76, 230-6	1.8	41
137	Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. *Wiener Klinische Wochenschrift*, **2003**, 115, 485-504	2.3	22
136	Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. *Genes Chromosomes and Cancer*, **2003**, 36, 80-9	5	31
135	ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. *Transfusion*, **2003**, 43, 1153-61	2.9	62
134	Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?. *British Journal of Haematology*, **2003**, 120, 310-4	4.5	29
133	Glycoprotein Ib polymorphisms influence platelet plug formation under high shear rates. *British Journal of Haematology*, **2003**, 120, 652-5	4.5	24

132	The E-selectin S128R polymorphism is not a risk factor for coronary artery disease in patients with diabetes mellitus type 2. *Thrombosis Research*, **2003**, 112, 47-50	8.2	20
131	The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. *Thrombosis Research*, **2003**, 110, 181-6	8.2	63
130	Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. *Clinica Chimica Acta*, **2003**, 330, 31-55	6.2	83
129	Akute myeloische Leukmien **2003**, 312-350		
128	Comparison of methods for determination of interleukin 6 G(-174)C promoter polymorphism. *BioTechniques*, **2002**, 33, 1114-7	2.5	9
127	Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. *American Journal of Hematology*, **2002**, 71, 1-6	7.1	71
126	The K121Q polymorphism in the plasma cell membrane glycoprotein 1 gene predisposes to early myocardial infarction. *Journal of Molecular Medicine*, **2002**, 80, 791-5	5.5	30
125	Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. *British Journal of Haematology*, **2002**, 117, 399-404	4.5	312
124	Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning. *British Journal of Haematology*, **2002**, 118, 132-5	4.5	3
123	Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. *Diabetes*, **2002**, 51, 3582-5	0.9	59
122	The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. *Archives of Internal Medicine*, **2002**, 162, 2357-60		51
121	Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. *Journal of Endovascular Therapy*, **2002**, 9, 385-94	2.5	35
120	Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. *Blood*, **2002**, 100, 1060-2	2.2	149
119	Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. *Blood*, **2002**, 100, 2267-8	2.2	34
118	Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. *Chest*, **2002**, 121, 286-9	5.3	20
117	Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. *Thrombosis Research*, **2002**, 106, 131-6	8.2	91
116	Heme Oxygenase-1 Genotype Is a Vascular Anti-inflammatory Factor Following Balloon Angioplasty. *Journal of Endovascular Therapy*, **2002**, 9, 385-394	2.5	17
115	Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). *The Hematology Journal*, **2002**, 3, 283-9		59

114	Homozygosity for the C-->T polymorphism at nucleotide 46 in the 5N untranslated region of the factor XII gene protects from development of acute coronary syndrome. *British Journal of Haematology*, **2001**, 115, 1007-9	4.5	31
113	PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR. *Transfusion*, **2001**, 41, 111-6	2.9	
112	Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. *Leukemia*, **2001**, 15, 355-61	10.7	18
111	Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. *Leukemia*, **2001**, 15, 635-41	10.7	12
110	Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation. *European Journal of Haematology*, **2001**, 67, 165-9	3.8	4
109	Preeclampsia and fetal loss in women with a history of venous thromboembolism. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 874-9	9.4	59
108	CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. *Leukemia and Lymphoma*, **2001**, 42, 823-9	1.9	48
107	Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. *Journal of Endovascular Therapy*, **2001**, 8, 433-40	2.5	155
106	A common C-->T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. *Thrombosis Research*, **2001**, 101, 255-60	8.2	39
105	Combined occurrence of a heterozygous missense mutation in the protein C gene and allelic exclusion of one protein S allele leading to severe venous thrombosis. *Thrombosis Research*, **2001**, 103, 3-8	8.2	5
104	Multiplexed Mutagenically Separated PCR: Simultaneous Single-Tube Detection of the Factor V R506Q (G1691A), the Prothrombin G20210A, and the Methylenetetrahydrofolate Reductase A223V (C677T) Variants. *Clinical Chemistry*, **2001**, 47, 333-335	5.5	26
103	Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Restenosis After Percutaneous Transluminal Angioplasty. *Journal of Endovascular Therapy*, **2001**, 8, 433-440	2.5	45
102	Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. *Cancer Research*, **2001**, 61, 1629-36	10.1	73
101	Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. *British Journal of Haematology*, **2000**, 109, 622-8	4.5	21
100	The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. *British Journal of Haematology*, **2000**, 110, 469-71	4.5	41
99	P53 - vom prognostischen zum prädiktiven Marker*). *European Surgery - Acta Chirurgica Austriaca*, **2000**, 32, 68-72	0.9	
98	Variant intra philadelphia translocation with rearrangement of BCR-ABL and ABL-BCR within the same chromosome in a patient with cALL. *Cancer Genetics and Cytogenetics*, **2000**, 122, 83-6		2
97	Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia. *Annals of Hematology*, **2000**, 79, 206-13	3	4

96	Evaluation of a highly specific functional test for the detection of factor V Leiden. *International Journal of Clinical and Laboratory Research*, **2000**, 30, 113-7		13
95	Follicular lymphomas□BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. *Blood*, **2000**, 95, 3520-3529	2.2	135
94	Protein S Deficiency: A Database of Mutations □Summary of the First Update. *Thrombosis and Haemostasis*, **2000**, 84, 918-918	7	74
93	Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T-(NK/T-) cell lymphomas. *Modern Pathology*, **2000**, 13, 766-72	9.8	70
92	Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. *Gut*, **2000**, 46, 133-5	19.2	55
91	Evaluation of RNA isolation methods and reference genes for RT-PCR analyses of rare target RNA. *Clinical Chemistry and Laboratory Medicine*, **2000**, 38, 171-7	5.9	56
90	P53 □vom prognostischen zum pr□diktiven Marker. *Acta Chirurgica Austriaca*, **2000**, 32, 68-72		
89	Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. *The Hematology Journal*, **2000**, 1, 37-41		46
88	The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene. *Thrombosis and Haemostasis*, **1999**, 81, 14-17	7	114
87	Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. *British Journal of Haematology*, **1999**, 105, 912-9	4.5	19
86	Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. *British Journal of Haematology*, **1999**, 106, 634-43	4.5	45
85	Homocysteine levels in polycythaemia vera and essential thrombocythaemia. *British Journal of Haematology*, **1999**, 105, 551-555	4.5	36
84	Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR. *Leukemia*, **1999**, 13, 1519-24	10.7	37
83	Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemia. *Bone Marrow Transplantation*, **1999**, 23, 753-8	4.4	6
82	Genetic fingerprinting in mouthwashes of patients after allogeneic bone marrow transplantation. *Bone Marrow Transplantation*, **1999**, 24, 95-8	4.4	45
81	Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation. *Annals of Hematology*, **1999**, 78, 376-9	3	9
80	Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. *Annals of Hematology*, **1999**, 78, 507-13	3	19
79	Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. *Translational Research*, **1999**, 133, 575-82		26

78	C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. *Thrombosis Research*, **1999**, 93, 61-9	8.2	43
77	The Factor V (Leiden) test: evaluation of an assay based on dilute Russell Viper Venom Time for the detection of the Factor V Leiden mutation. *Thrombosis Research*, **1999**, 96, 125-33	8.2	16
76	Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. *American Journal of Clinical Pathology*, **1999**, 112, 93-100	1.9	51
75	Combined polymerase chain reaction approach for clonality detection in lymphoid neoplasms. *Diagnostic Molecular Pathology*, **1999**, 8, 80-91		29
74	No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene. *Blood Coagulation and Fibrinolysis*, **1999**, 10, 101-5	1	23
73	Faktor XII: Biochemie, Molekularbiologie, Physiologie **1999**, 122-131		1
72	Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors. *Bone Marrow Transplantation*, **1998**, 21, 673-8	4.4	26
71	K-ras mutations as pathogenetic and diagnostic markers in pancreatic cancer. *Acta Chirurgica Austriaca*, **1998**, 30, 196-197		
70	Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia. *Annals of Hematology*, **1998**, 77, 283-6	3	6
69	Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. *Kidney International*, **1998**, 53, 1775-82	9.9	62
68	Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. *American Journal of Pathology*, **1998**, 153, 1483-90	5.8	172
67	677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocyst(e)ine levels in patients with TIA or minor stroke. *Journal of the Neurological Sciences*, **1998**, 155, 156-62	3.2	8
66	Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. *Blood Coagulation and Fibrinolysis*, **1998**, 9, 85-9	1	21
65	A Single Genetic Origin for the Common Prothrombotic G20210A Polymorphism in the Prothrombin Gene. *Blood*, **1998**, 92, 1119-1124	2.2	162
64	Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway. *Thrombosis Research*, **1997**, 87, 501-10	8.2	21
63	Donor Leukocyte Infusion for Leukemic Relapse After Allogeneic Marrow Transplantation: Lack of Residual Donor Hematopoiesis Predicts Aplasia. *Blood*, **1997**, 89, 3113-3117	2.2	101
62	Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. *Kidney International*, **1997**, 52, 517-23	9.9	88
61	Molecular genetics and development of mast cells: implications for molecular medicine. *Trends in Molecular Medicine*, **1997**, 3, 131-7		9

60	Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes. *British Journal of Haematology*, **1997**, 97, 161-4	4.5	23
59	A hitherto unknown splice site defect in the protein S gene (PROS1): the mutation results in allelic exclusion and causes type I and type III protein S deficiency. *British Journal of Haematology*, **1997**, 99, 298-300	4.5	6
58	The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden. *Thrombosis and Haemostasis*, **1997**, 77, 624-628	7	141
57	Prothrombin Fragment F1+2 Is not Predictive for Recurrent Venous Thromboembolism. *Thrombosis and Haemostasis*, **1997**, 77, 0829-0833	7	21
56	Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. *Nephrology Dialysis Transplantation*, **1996**, 11, 668-72	4.3	31
55	Common IgE-epitopes of recombinant Phl p I, the major timothy grass pollen allergen and natural group I grass pollen isoallergens. *Molecular Immunology*, **1996**, 33, 417-26	4.3	37
54	Two New Frequent Dimorphisms in the Protein S (PROS1) Gene*. *Thrombosis and Haemostasis*, **1996**, 76, 393-396	7	11
53	Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma. *American Journal of Clinical Pathology*, **1996**, 106, 588-93	1.9	27
52	A multilocular B-cell neoplasia presenting as multiple myeloma and polymorphic lymphoma of recipient origin 2 months after kidney transplantation in a heart-transplant recipient. *Nephrology Dialysis Transplantation*, **1996**, 11, 2085-7	4.3	3
51	Identification of a variable number tandem repeat region in the human T cell receptor alpha-delta (TCRAD) locus. *Human Genetics*, **1996**, 98, 333-5	6.3	4
50	Screening by genomic linkage studies and mutation analysis of hereditary adenomatous polyposis coli: usefulness for clinical practice. *World Journal of Surgery*, **1996**, 20, 578-83; discussion 583-4	3.3	3
49	FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. *Annals of Hematology*, **1996**, 73, 265-71	3	54
48	Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. *Journal of Thoracic and Cardiovascular Surgery*, **1996**, 111, 827-31; discussion 832	1.5	18
47	Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. *Annals of Hematology*, **1996**, 72, 53-9	3	4
46	Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. *British Journal of Haematology*, **1996**, 93, 487-90	4.5	60
45	Multiplex PCR for rapid detection of T-cell receptor-gamma chain gene rearrangements in patients with lymphoproliferative diseases. *British Journal of Haematology*, **1996**, 94, 136-9	4.5	38
44	Graft failure after donor leucocyte infusion in relapsed chronic myeloid leukaemia: successful treatment with cyclophosphamide and antithymocyte globulin followed by peripheral blood stem cell infusion. *British Journal of Haematology*, **1996**, 94, 120-2	4.5	12
43	G-CSF stimulation of donor myelopoiesis prolongs survival of relapsed BCR-ABL-positive acute lymphoblastic leukemia after allogeneic marrow transplantation. *Bone Marrow Transplantation*, **1996**, 18, 655-7	4.4	2

42	Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. *Annals of Hematology*, **1996**, 72, 53-59	3	
41	PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **1995**, 89, 937-41	4.5	30
40	Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. *Annals of Hematology*, **1995**, 71, 155-60	3	7
39	Protein S deficiency type I: identification of point mutations in 9 of 10 families. *Blood*, **1995**, 86, 3444-3451	2.2	40
38	Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis. *Gastroenterology*, **1995**, 109, 2015-8	13.3	40
37	Protein S deficiency type I: identification of point mutations in 9 of 10 families. *Blood*, **1995**, 86, 3444-51	2.2	3
36	Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia **1995**, 71, 155		1
35	Carcinogen-specific mutations in the p53 tumor suppressor gene in lung cancer. *Journal of Thoracic and Cardiovascular Surgery*, **1994**, 107, 1095-1098	1.5	12
34	Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. *Blood*, **1994**, 84, 2954-2959	2.2	94
33	Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. *Blood*, **1994**, 84, 2954-2959	2.2	3
32	The Prevalence of Moderate and Severe FXII (Hageman Factor) Deficiency among the Normal Population: Evaluation of the Incidence of FXII Deficiency among 300 Healthy Blood Donors. *Thrombosis and Haemostasis*, **1994**, 71, 068-072	7	67
31	Twelve novel and two recurrent mutations in 14 Austrian families with hereditary protein C deficiency. *Blood Coagulation and Fibrinolysis*, **1993**, 4, 273-80	1	24
30	Mechanism of the chromosomal translocation t(14;18) in lymphoma: detection of a 45-Kd breakpoint binding protein. *Blood*, **1993**, 81, 1833-1840	2.2	37
29	Plasma protein adsorption to hemodialysis membranes: studies in an in vitro model. *Journal of Biomedical Materials Research Part B*, **1993**, 27, 455-63		17
28	Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1. *Journal of Cellular Physiology*, **1993**, 156, 358-66	7	6
27	Biocompatibility of artificial surfaces such as cellulose and related materials. *Sensors and Actuators B: Chemical*, **1993**, 11, 273-279	8.5	15
26	Adsorption of coagulation factors on to haemodialysis membranes during standard haemodialysis. *Journal of Materials Science: Materials in Medicine*, **1993**, 4, 12-16	4.5	3
25	Hypergranular acute lymphoblastic leukemia (ALL). Report of a case and review of the literature. *Annals of Hematology*, **1993**, 67, 301-3	3	11

24	Mechanism of the chromosomal translocation t(14;18) in lymphoma: detection of a 45-Kd breakpoint binding protein. *Blood*, **1993**, 81, 1833-1840	2.2	2
23	Genetik und kolorektales Karzinom. *Acta Chirurgica Austriaca*, **1992**, 24, 94-99		
22	The Prevalence of Factor XII Deficiency in 103 Orally Anticoagulated Outpatients Suffering from Recurrent Venous and/or Arterial Thromboembolism. *Thrombosis and Haemostasis*, **1992**, 68, 285-290	7	83
21	Faktor XII-Mangel und Thrombophilie **1992**, 184-188		
20	Detection of engraftment and mixed chimerism following bone marrow transplantation using PCR amplification of a highly variable region-variable number of tandem repeats (VNTR) in the von Willebrand factor gene. *Annals of Hematology*, **1991**, 63, 227-8	3	33
19	C1-Esterase Inhibitor in Uncomplicated Pregnancy and Mild and Moderate Preeclampsia. *Thrombosis and Haemostasis*, **1991**, 65, 134-138	7	17
18	Effects of 3-azidothymidine on platelet counts, indium-111-labelled platelet kinetics, and antiplatelet antibodies. *Vox Sanguinis*, **1989**, 57, 120-6	3.1	9
17	Identification of the target platelet glycoprotein in autoimmune thrombocytopenia occurring after allogeneic bone marrow transplantation. *Blut*, **1989**, 58, 151-3		17
16	Commercial immunodepleted deficient plasmas contain cleaved high molecular weight kininogen (HK). *Thrombosis and Haemostasis*, **1988**, 60, 447-52	7	
15	Biochemical and functional properties of factor XI and prekallikrein. *Seminars in Thrombosis and Hemostasis*, **1987**, 13, 25-35	5.3	8
14	Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. *Fibrinolysis*, **1987**, 1, 259-263		85
13	Clotting activities and antigen concentrations of contact factors in kidney disease. *Thrombosis Research*, **1985**, 39, 475-84	8.2	3
12	Phospholipids accelerate factor IX activation by surface bound factor XIa. *British Journal of Haematology*, **1984**, 56, 261-71	4.5	19
11	The effect of synthetic polymer surfaces on the activation of factor XI in plasma: influence of heparin. *Thrombosis Research*, **1984**, 35, 713-8	8.2	5
10	CRM+ severe Fletcher factor deficiency associated with GravesN disease. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1984**, 14, 302-6		3
9	Prekallikrein, HMW-kininogen and factor XII in various disease states. *Thrombosis Research*, **1983**, 31, 351-64	8.2	11
8	Surface Adsorption of Factor XI: II. Evidence that Different Mechanisms Are Involved in Binding to Glass and Plastic Materials. *Thrombosis and Haemostasis*, **1982**, 47, 214-217	7	3
7	Contact activation of factor XI. *British Journal of Haematology*, **1981**, 49, 77-86	4.5	4

6	Human high molecular weight kininogen. Effects of cleavage by kallikrein on protein structure and procoagulant activity. *Journal of Biological Chemistry*, **1980**, 255, 6433-8	5.4	42
5	Trypsin activation of human factor XI. *Journal of Biological Chemistry*, **1980**, 255, 2667-9	5.4	19
4	Human high molecular weight kininogen. Effects of cleavage by kallikrein on protein structure and procoagulant activity.. *Journal of Biological Chemistry*, **1980**, 255, 6433-6438	5.4	45
3	Trypsin activation of human factor XI.. *Journal of Biological Chemistry*, **1980**, 255, 2667-2669	5.4	19
2	Surface Adsorption of Factor XI: Association of Adsorption Sites with the Heavy Chain of Activated Factor XI. *Thrombosis and Haemostasis*, **1980**, 43, 124-126	7	6
1	Studies on the prothrombin--complex. *Thrombosis Research*, **1979**, 14, 67-75	8.2	1